GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (STU:6JH0) » Definitions » Return-on-Tangible-Asset

IN8bio (STU:6JH0) Return-on-Tangible-Asset : -107.01% (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is IN8bio Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. IN8bio's annualized Net Income for the quarter that ended in Mar. 2025 was €-20.54 Mil. IN8bio's average total tangible assets for the quarter that ended in Mar. 2025 was €19.19 Mil. Therefore, IN8bio's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -107.01%.

The historical rank and industry rank for IN8bio's Return-on-Tangible-Asset or its related term are showing as below:

STU:6JH0' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -146.16   Med: -77.65   Max: -35.3
Current: -130.81

During the past 7 years, IN8bio's highest Return-on-Tangible-Asset was -35.30%. The lowest was -146.16%. And the median was -77.65%.

STU:6JH0's Return-on-Tangible-Asset is ranked worse than
84.79% of 1499 companies
in the Biotechnology industry
Industry Median: -36.14 vs STU:6JH0: -130.81

IN8bio Return-on-Tangible-Asset Historical Data

The historical data trend for IN8bio's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IN8bio Return-on-Tangible-Asset Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial -77.28 -47.54 -78.55 -88.62 -114.18

IN8bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.80 -144.42 -144.75 -136.87 -107.01

Competitive Comparison of IN8bio's Return-on-Tangible-Asset

For the Biotechnology subindustry, IN8bio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IN8bio's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where IN8bio's Return-on-Tangible-Asset falls into.


;
;

IN8bio Return-on-Tangible-Asset Calculation

IN8bio's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-29.067/( (30.911+20.002)/ 2 )
=-29.067/25.4565
=-114.18 %

IN8bio's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-20.536/( (20.002+18.379)/ 2 )
=-20.536/19.1905
=-107.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


IN8bio  (STU:6JH0) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


IN8bio Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of IN8bio's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


IN8bio Business Description

Industry
Traded in Other Exchanges
Address
350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

IN8bio Headlines

No Headlines